ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

DCE Board Sets Aside $2 Million For Radiation Grants Program; Okays Concept For Add-On To ASCUS Trial

October 13, 1995

DeVita Era At NCI One Of New Programs, Remarkable Stability

August 19, 1988

Coooperative Groops Announce Two Sets of Mergers: NSABP, RTOG Form Alliance; CALGB, NCCTG & ACOSOG Seek to Become Single Group

March 11, 2011

Letters To the Editor: NCI director Broder responds To Kopans On Mammography

October 8, 1993

Cancer Advocacy: Jay Hedlund Resigns As NPCC President

May 14, 1999

Also NCI prostate SPOREs plan biospecimen bank.

December 10, 2004